Cheers! Broker tips 20% upside for the Treasury Wine (ASX:TWE) share price

This wine giant could be in the buy zone…

| More on:
rising ASX share price represented by cork popping out of wine bottle

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • Treasury Wine's shares could be great value according to one leading broker.
  • It was impressed with its performance during the first half of FY 2022 and expects more of the same in the future.
  • Morgans sees potential upside of almost 20% over the next 12 months.

The Treasury Wine Estates Ltd (ASX: TWE) share price could be great value at the current level.

That's the view of analysts at Morgans, who have retained their positive view on the wine company's shares following its half year results.

What is Morgans saying about the Treasury Wine share price?

According to a recent note, the broker has retained its add rating but trimmed its price target on the company's shares slightly to $13.93.

Based on the current Treasury Wine share price of $11.66, this implies potential upside of almost 20% for investors over the next 12 months.

In addition, the broker has pencilled in a fully franked 29 cents per share dividend in FY 2022. If you include this ~2.5% yield, the total potential return on offer increases to 22%.

Why is the broker positive?

Morgans notes that Treasury Wine outperformed its expectations during the first half.

It commented: "Treasury Wine Estates reported an impressive 1H22 result given it had to cycle China earnings and the divested US commercial wine portfolio. COVID also continued to impact some of its higher margin channels. The result materially beat our forecast but was in line with consensus expectations."

Pleasingly, the broker expects this strong form to continue in the second half and in FY 2023.

In respect to the latter, the broker said: "In FY23, TWE's earnings will benefit from the recovery of its higher margin channels, its new divisional operating model, Penfolds reallocation strategy, a full year of the FFV acquisition and the associated synergies and lower COGS, with management expecting to deliver cost savings of at least A$75m pa."

In light of this and the attractive multiples that the Treasury Wine share price trades on compared to peers and historic averages, the broker sees the company as a great option for investors.

It concludes: "Following forecast changes, our SOTP valuation has fallen to $13.93. With over 18% [now 19.5%] upside to our new price target and the stock trading on an FY23 PE of only 21x (long-term average is 25x) and a material discount to other luxury brand owners, we remain buyers of this well managed company."

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended Treasury Wine Estates Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Broker Notes

A man sits in deep thought with a pen held to his lips as he ponders his computer screen with a laptop open next to him on his desk in a home office environment.
Broker Notes

Brokers name 3 ASX shares to buy now

Here's why brokers are feeling bullish about these three shares this week.

Read more »

Research, collaboration and doctors working digital tablet, analysis and discussion of innovation cancer treatment. Healthcare, teamwork and planning by experts sharing idea and strategy for surgery.
Healthcare Shares

'Obvious buying opportunity': Top broker says beaten-up ASX All Ords stock has 253% upside

Wilsons analysts say the market has misread top-line medical trial results released this week.

Read more »

Senior woman using cpap machine to stop choking and snoring from obstructive sleep apnoea with bokeh and morning light background.
Broker Notes

Should you pounce on ResMed shares at around $28?

Here's what top broker Citi says.

Read more »

Three people in a corporate office pour over a tablet, ready to invest.
Broker Notes

Top brokers name 3 ASX shares to buy today

Here's what brokers are recommending as buys this week.

Read more »

ANZ ASX 200 banks capital return Group of investors madly grabbing for cash on city street.
Healthcare Shares

ResMed shares rebounding as investors rush to buy the dip

ResMed is rising as ASX investors buy the dip following yesterday's 13% share price dive.

Read more »

A group of stockbrokers sit in a room with several computer screens in front of them as they discuss the Zip share price and Zip's merger with Sezzle
Broker Notes

Why these 3 ASX 200 shares just gained significant broker upgrades

The brokers just boosted their outlooks for these ASX 200 shares. But why?

Read more »

A man holding a cup of coffee puts his thumb up and smiles while at laptop.
Broker Notes

Buy this ASX 200 stock for 'stability and growth potential'

One analyst has good things to say about this stock.

Read more »

A female executive smiles as she carries out business on her mobile phone.
Broker Notes

Buy Telstra shares due to its 'excessive' discount

This telco giant's shares could be unnecessarily cheap according to Bell Potter.

Read more »